Tevogen (TVGN) Payables (2021 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Payables came in at $5.4 million in Q1 2026, down 13.71% YoY from $6.3 million in Q1 2025, and up 63.16% on a QoQ basis from $3.3 million in Q4 2025.
Tevogen (TVGN) Payables (2021 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 6 years of Payables data on file, last reported at $5.4 million in Q1 2026.
- Quarterly Payables fell 13.71% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (down 13.71% YoY) and the FY2025 annual result came in at $3.3 million, down 35.77% from the prior year.
- Payables climbed to $5.4 million in Q1 2026, from $3.3 million in the prior quarter.
- In the past five years, Payables ranged from a high of $84.1 million in Q4 2023 to a low of $128999.0 in Q1 2022.
- A 5-year average of $8.4 million and a median of $5.0 million in 2025 frame the typical range for Payables.
- Annual changes were most pronounced in 2023 — Payables jumped 39875.66% — and 2024, when it slumped 93.82%.
- Tracing TVGN's Payables over 5 years: stood at $210454.0 in 2022, then jumped by 39875.66% to $84.1 million in 2023, then tumbled by 93.82% to $5.2 million in 2024, then plunged by 35.77% to $3.3 million in 2025, then soared by 63.16% to $5.4 million in 2026.
- The last three Payables figures came in at $5.4 million (Q1 2026), $3.3 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 35.57 Mn |
| 10 | Tevogen | 26.21 Mn | 26.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.45 Mn |
| Dec 31, 2025 | 3.34 Mn |
| Sep 30, 2025 | 4.96 Mn |
| Jun 30, 2025 | 5.89 Mn |
| Mar 31, 2025 | 6.32 Mn |
| Dec 31, 2024 | 5.20 Mn |
| Sep 30, 2024 | 7.49 Mn |
| Jun 30, 2024 | 8.32 Mn |
| Mar 31, 2024 | 6.86 Mn |
| Dec 31, 2023 | 84.13 Mn |
| Sep 30, 2023 | 1.63 Mn |
| Jun 30, 2023 | 1.32 Mn |
| Mar 31, 2023 | 485,074.00 |
| Dec 31, 2022 | 210,454.00 |
| Sep 30, 2022 | 171,783.00 |
| Jun 30, 2022 | 179,234.00 |
| Mar 31, 2022 | 128,999.00 |
| Dec 31, 2021 | 39,375.00 |